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MaBACKGROUND There are no data available on speciﬁc causes of death from randomized trials that have compared
coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI).
OBJECTIVES The purpose of this study was to investigate speciﬁc causes of death, and its predictors, after revascu-
larization for complex coronary disease in patients.
METHODS An independentClinicalEventsCommitteeconsistingofexpertphysicianswhowereblindedtothestudy treatment
subclassiﬁed causes of death as cardiovascular (cardiac and vascular), noncardiovascular, or undetermined according to the trial
protocol. Cardiac deaths were classiﬁed as sudden cardiac, related to myocardial infarction (MI), and other cardiac deaths.
RESULTS In the randomized cohort, there were 97 deaths after CABG and 123 deaths after PCI during a 5-year follow-up.
After CABG, 49.4% of deaths were cardiovascular, with the greatest cause being heart failure, arrhythmia, or other causes
(24.6%), whereas after PCI, the majority of deaths were cardiovascular (67.5%) and as a result of MI (29.3%). The
cumulative incidence rates of all-cause death were not signiﬁcantly different between CABG and PCI (11.4% vs. 13.9%,
respectively; p ¼ 0.10), whereas there were signiﬁcant differences in terms of cardiovascular (5.8% vs. 9.6%, respec-
tively; p¼ 0.008) and cardiac death (5.3% vs. 9.0%, respectively; p¼ 0.003), which were caused primarily by a reduction
in MI-related death with CABG compared with PCI (0.4% vs. 4.1%, respectively; p <0.0001). Treatment with PCI versus
CABGwas an independent predictor of cardiac death (hazard ratio: 1.55; 95% conﬁdence interval: 1.09 to 2.33; p¼0.045).
The difference in MI-related death was seen largely in patients with diabetes, 3-vessel disease, or high SYNTAX (TAXUS
Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial scores.
CONCLUSIONS During a 5-year follow-up, CABG in comparison with PCI was associated with a signiﬁcantly reduced
rate of MI-related death, which was the leading cause of death after PCI. Treatments following PCI should target reducing
post-revascularization spontaneous MI. Furthermore, secondary preventive medication remains essential in reducing
events post-revascularization. (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of
Narrowed Arteries [SYNTAX]; NCT00114972) (J Am Coll Cardiol 2016;67:42–55) © 2016 by the American College of
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43AB BR E V I A T I O N S
AND ACRONYM S
3VD = 3-vessel disease
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CEC = Clinical Events
Committee
CHF = congestive heart failure
CI = conﬁdence interval
DES = drug-eluting stent
HR = hazard ratio
LM = left main
MI = myocardial infarction
PCI = percutaneous coronary
interventionC oronary artery bypass grafting (CABG) andpercutaneous coronary intervention (PCI)are both used for myocardial revasculariza-
tion in patients with complex coronary artery disease
(CAD) with an indication for revascularization (1). A
large number of studies have reported or compared
outcomes of CABG and PCI as optimum treatment
strategies (2), but data are limited on the causes, cir-
cumstances, and the mechanisms of death after these
procedures.
Observational studies have reported causes of
death after PCI and CABG (3–5), but these results are
difﬁcult to interpret because the cause of death may
not always be clear in retrospect. Therefore, data
from randomized trials in which a Clinical Events
Committee (CEC) adjudicates deaths provide more
valuable information. Two randomized clinical trials
that compared CABG with medical therapy have
shown that CABG was particularly effective in
reducing rates of sudden cardiac death (5,6), but no
comparisons between PCI and CABG on the speciﬁc
causes of death are available from randomized trials.SEE PAGE 56Assessment of the cause of death in contemporary
practice should help to target potential underlying
mechanisms of death and further develop effective
interventions to improve survival after myocardial
revascularization. The goal of the present study was
to investigate the speciﬁc cause of death, and its
predictors, in patients enrolled in the SYNTAX
(TAXUS Drug-Eluting Stent Versus Coronary Artery
Bypass Surgery for the Treatment of Narrowed Ar-
teries) trial, which represents a contemporary cohort
of patients who underwent CABG or received drug-
eluting stents (DES).
METHODS
STUDY DESIGN, PATIENTS, AND RANDOMIZATION.
The design, methods, and procedural details of the
SYNTAX trial have been reported previously (7–9).
The SYNTAX study was a prospective, multinational,
randomized trial conducted in 85 centers in the
United States and Europe. In this study, 1,800 patients
with de novo left main (LM) or 3-vessel disease
(3VD) were randomly assigned to undergo CABG or PCI
with ﬁrst-generation paclitaxel-eluting stents (Taxus
Express, Boston Scientiﬁc, Natick, Massachusetts).
Based on clinical judgment and consensus of a heart
team that consisted of a cardiac surgeon and inter-
ventional cardiologist at each center, patients with
anticipated clinical equipoise through CABG and PCI
were randomized (CABG, n ¼ 897 and PCI, n ¼ 903).Randomization occurred via a central inter-
active voice response system in random block
sizes per site based on the presence or absence
of LM disease and medically treated diabetes
mellitus. Patients suitable for PCI only entered
the PCI registry (CABG ineligible patients,
n ¼ 198), whereas those suitable for CABG
only entered the CABG registry (PCI ineligible
patients, n ¼ 1,077) (10). Within the nested
registries, all PCI patients and 649 randomly
allocated CABG patients underwent 5-year
follow-up. Routine follow-up assessments
were performed by clinical visits or telephone
interviews at 1, 6, and 12months, and annually
thereafter. All the clinical endpoints were
assessed by the event-adjudication CEC. Data
collection and quality were monitored sys-
tematically by the principal investigators and safety
monitoring committee. Complete 5-year follow-up
(clinical follow-up or death) after randomization to
CABG and PCI was achieved in 805 (89.7%) and 871
(96.5%) patients, respectively. Follow-up was com-
plete for 184 patients (95.8%) in the PCI registry and for
607 patients (94.3%) in the CABG registry.
The post-procedure medication regimens and the
use of secondary-prevention therapy according to
American College of Cardiology and American Heart
Association treatment guidelines (11,12) was strongly
recommended for all patients. Medication use for
the randomized cohort was collected at baseline,
discharge, at 1 and 6 months, and at 1, 3, and 5 years
post-allocation. For the nested registries, this was
collected at baseline and discharge.
This study was done in accordance with the prin-
ciples of the Declaration of Helsinki, and all site-
speciﬁc institutional review boards and applicable
regulatory agencies approved the study protocol
before study initiation.
DEFINITIONS. The deﬁnitions used for the classiﬁ-
cations of adverse events have been previously re-
ported elsewhere (9). Mortality data during the
course of follow-up were collected prospectively.
Collection started directly after randomization to
ﬁnalizing the 5-year follow-up; therefore, this
included post-randomization pre-procedural deaths,
operative deaths, and deaths during follow-up. For
each death event, standardized electronic case report
forms were used by local principal investigators to
categorize a terminal event in detail. The case report
form included a structured narrative description of
date and location of death, onset of adverse events
that preceded the fatal outcome, circumstances of
death, and description of treatments, if initiated. For
all deaths, all available information was obtained and
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44forwarded to the independent CEC, including the
death certiﬁcates, the coroner’s report, and other
records (hospital discharge summary, pathology,
laboratory, radiology, and other diagnostic data). The
CEC was composed of physicians who were experts
in cardiology, cardiac surgery, and neurology. Two
CEC members reviewed all deaths independently
in a blinded manner. Disagreements between re-
viewers and principal investigators were discussed
and resolved by full CEC consensus.
Because the SYNTAX study began before publica-
tion of the Academic Research Consortium deﬁnition
(13), it used specially designed deﬁnitions of death.
The CEC classiﬁed deaths into cardiovascular or non-
cardiovascular, according to the trial protocol. Car-
diovascular deaths were further classiﬁed as cardiac
(sudden cardiac deaths, myocardial infarction [MI],
progressive heart failure, and arrhythmia) and cardiac
others (which included other cardiac causes, e.g.,
cardiac tamponade and cardiac deaths with insufﬁ-
cient information for deﬁnitive classiﬁcation),
vascular (stroke, aortic dissection, and pulmonary
embolism), and vascular others (major hemorrhage,
peripheral embolism, and other). Using these classiﬁ-
cations, the following cardiac subgroups were deﬁned
and analyzed: 1) sudden cardiac deaths; 2) MI-related
deaths; and 3) congestive heart failure (CHF),
arrhythmia, and all other cardiac deaths, the latter of
which were combined together into a single subgroup
because of the low number of cases in each particular
subgroup. Noncardiovascular deaths included those
resulting from chronic respiratory disease, pneu-
monia, malignancy, diabetes mellitus, and other con-
ditions (which included infections, accidents,
suicides, trauma-related, chronic disease, and others).
When a speciﬁc cause of death could not be deter-
mined from the available evidence, the death was
classiﬁed as undetermined. Every death was attrib-
uted to one of the speciﬁc causes exclusively.
Major adverse events were considered nonfatal if
no death occurred within 30 days of the event, and
when it was not possible to establish any association
between the event and death from the narrative
description of death.
During the Heart Team meeting, both the inter-
ventional cardiologist and surgeon documented
which vessels that were $1.5 mm diameter and >50%
stenosis needed revascularization. In the original trial
protocol, incomplete revascularization was deﬁned
when the actual revascularization did not correlate
with this pre-operative Heart Team statement.
STATISTICAL ANALYSES. All analyses in the randomized
cohort were done according to the intention-to-treatprinciple, whereas in the nested registries, out-
comes were presented according to the as-treated
principle. As previously described, no statistical com-
parisons between the PCI and CABG registries were
performed (10).
Continuous variables were reported as mean  SD
and compared with the Student t test. Binary vari-
ables were expressed as counts and/or percentages
and compared with the chi-square test or Fisher
exact test, as appropriate. Five-year rates of death
were estimated using the Kaplan-Meier method, and
comparisons between PCI and CABG were done using
the log-rank test. For the randomized cohort, sub-
group analyses were performed for pre-speciﬁed
groups of patients with LM or 3VD and diabetic pa-
tients or nondiabetic patients, and post-hoc groups
according to SYNTAX score tertiles (low 0 to 22,
intermediate 23 to 32, and high $33) and complete-
ness of revascularization. The p values for interaction
were performed using chi-square tests. Cox propor-
tional hazard models for speciﬁc causes of death
during the 5-year follow-up were constructed to
provide hazard ratios (HRs) associated with PCI
versus CABG treatment. The proportional hazards
assumption of the Cox models was evaluated with
Schoenfeld residuals (14). There was no evidence of
departure from the assumption of proportionality.
Multivariate analyses were performed using Cox
proportional hazard models with backward selection
of variables to construct a set of independent pre-
dictors. Variables considered of clinical importance
and with a p value <0.15 in univariate analysis were
considered in the multivariate models (Online
Appendix). Models were constructed for the overall
randomized cohort and CABG and PCI randomized
groups separately, as well as for the PCI and CABG
registry patients separately. The performance of the
models was tested using receiver-operating charac-
teristics curves. A 2-sided p value of <0.05 was
considered to be statistically signiﬁcant for all tests.
Analyses were performed using SPSS version 20.0
statistical software (IBM, Armonk, New York).
RESULTS
CAUSES OF DEATH. During the 5-year follow-up,
there were 123 deaths after PCI and 97 deaths after
CABG in the randomized cohort. Among PCI patients,
the majority of deaths were cardiovascular (67.5%,
n ¼ 83), of which nearly all deaths were from cardiac
causes (Table 1). The largest cause of cardiovascular
death after PCI was related to MI (Figure 1A). In
the CABG group, cardiovascular deaths accounted for
49.4% (n ¼ 48), noncardiovascular deaths for 48.5%
TABLE 1 Speciﬁc Causes of Death in the SYNTAX Trial
Causes of Death PCI CABG HR (95% CI) p Value PCI Registry CABG Registry
Total 123 (13.9) 97 (11.4) 1.23 (0.94–1.60) 0.10 57 (30.0) 79 (12.6)
Cardiovascular death 83 (9.6) 48 (5.8) 1.62 (1.13–2.31) 0.008 22 (12.1) 29 (4.7)
Cardiac 78 (9.0) 43 (5.3) 1.70 (1.17–2.47) 0.003 17 (9.5) 22 (3.6)
Sudden cardiac death 24 (2.8) 15 (1.9) 1.61 (0.83–3.11) 0.16 5 (2.7) 6 (1.0)
Myocardial infarction 36 (4.1) 4 (0.4) 8.43 (2.99–23.67) <0.0001 3 (1.8) 2 (0.3)
Heart failure 7 (0.8) 13 (1.6) 0.50 (0.20–1.26) 0.14 5 (2.7) 6 (1.0)
Arrhythmia 1 (0.1) 1 (0.1) 0.95 (0.06–15.14) 0.97 0 1 (0.2)
Other 10 (1.1) 11 (1.4) 0.85 (0.36–2.01) 0.71 4 (2.2) 6 (1.0)
CHF/cardiac other 18 (2.1) 24 (3.0) 0.67 (0.37–1.24) 0.20 9 (4.8) 14 (2.2)
Vascular 5 (0.6) 5 (0.5) 0.93 (0.27–3.23) 0.91 5 (2.7) 7 (1.1)
CVA 3 (0.3) 3 (0.3) 0.94 (0.19–4.64) 0.94 1 (0.5) 3 (0.5)
Aortic dissection 0 0 – >0.99 0 2 (0.3)
Pulmonary embolism 0 1 (0.1) 0.014 (0–138,818) 0.60 2 (1.1) 0
Other 2 (0.2) 1 (0.1) 1.86 (0.17–20.55) 0.61 2 (1.1) 2 (0.3)
Noncardiovascular death 40 (4.3) 47 (5.6) 0.85 (0.55–1.31) 0.46 29 (14.9) 33 (5.3)
Chronic respiratory disease 0 1 (0.1) 0.015 (0–141,247) 0.61 3 (1.8) 1 (0.2)
Pneumonia 4 (0.4) 3 (0.3) 1.88 (0.34–10.29) 0.46 6 (3.1) 3 (0.5)
Cancer 20 (2.2) 20 (2.4) 1.04 (0.55–1.97) 0.90 8 (4.2) 20 (3.1)
DM 1 (0.1) 0 60.88 (0–595,324) 0.62 0 1 (0.2)
Other 15 (1.6) 23 (2.8) 0.61 (0.32–1.17) 0.14 12 (5.9) 8 (1.3)
Undetermined death 0 2 (0.2) 0.016 (0–1262) 0.47 6 (3.1) 17 (2.6)
Values are number of events (%), unless otherwise indicated.
CABG ¼ coronary artery bypass grafting; CHF ¼ congestive heart failure; CI ¼ conﬁdence interval; CVA ¼ cerebral vascular accident; DM ¼ diabetes mellitus; HR ¼ hazard
ratio; PCI ¼ percutaneous coronary intervention; SYNTAX ¼ TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries.
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45(n ¼ 47), and 2.1% (n ¼ 2) of deaths occurred due to
undetermined causes (Table 1). Of cardiovascular
death, only a few deaths were from vascular causes.
The greatest cause of cardiovascular death after CABG
was CHF, arrhythmia, or other causes (Figure 1A).
In the PCI registry, 22 (38.6%) patients died of
cardiovascular causes, and the majority of deaths
(50.9%, n ¼ 33) were due to noncardiovascular causes
(Figure 1B). Within the CABG registry, cardiovascular
deaths represented 36.7% (n ¼ 29) of deaths, whereas
noncardiovascular deaths occurred in 41.8% (n ¼ 33)
of cases. Of note, noncardiovascular deaths were
most often caused by malignancies.
INCIDENCES OF DEATH. At 5-year follow-up, there
was a signiﬁcant difference in favor of CABG in terms
of cardiovascular death (p ¼ 0.008), but not of non-
cardiovascular death (p ¼ 0.46) (Figure 2). The dif-
ference in cardiovascular death was the result of
a signiﬁcantly lower rate of death due to MI (CABG
0.4% vs. PCI 4.1%; p < 0.0001), whereas rates of
sudden cardiac death or death by CHF or arrhythmia
were similar. All-cause death rates were not signiﬁ-
cantly different (p ¼ 0.10) (Figure 2).
Rates of all-cause death at 5-year follow-up were
30.0% (n ¼ 57) in the PCI registry and 12.6% (n ¼ 79) in
the CABG registry (Table 1). Speciﬁc causes of death
are shown in Figure 3.SUBGROUP ANALYSES. Subgroup analyses revealed
that the reduced rates of cardiac death after CABG in
comparison with PCI were particularly evident in
patients with diabetes, 3VD, and a high SYNTAX
score, although none of the interaction tests were
signiﬁcant (Figure 4A). More in-depth subgroup ana-
lyses in rates of sudden cardiac deaths, MI-related
deaths, and CHF and/or other cardiac deaths were
performed to detect the cause of this difference
(Figure 4B). Among all patient subgroups, the rate of
sudden cardiac death was numerically higher after
PCI than after CABG, although this failed to reach
statistical signiﬁcance. Only patients with a high
SYNTAX score had signiﬁcantly higher rates of sud-
den cardiac death after PCI versus CABG (HR: 5.09;
95% conﬁdence interval [CI]: 1.46 to 17.71; p ¼ 0.011).
Differences in MI-related deaths were consistently in
favor of CABG and were particularly prominent in
patients with diabetes, 3VD, and higher SYNTAX
scores. There were no differences between PCI and
CABG in terms of deaths due to CHF or other cardiac
causes, although patients with a lower SYNTAX score
did appear to have a nonsigniﬁcant beneﬁt with PCI
(Figure 4B).
Incomplete revascularization with PCI was associ-
ated with risk of cardiac deaths (HR: 1.89; 95% CI: 1.20
to 2.98; p ¼ 0.006), which was driven by deaths due
FIGURE 1 Causes of Death in the SYNTAX Randomized Cohort and Nested Registries
PCI deaths, n=123 CABG deaths, n=97
PCI Registry deaths
(n=57)
CABG Registry deaths
(n=79)
Sudden cardiac death
MI death
CHF/Other cardiac death
Vascular death
Noncardiovascular death
Undetermined death
Sudden cardiac death
MI death
CHF/Other cardiac death
Vascular death
Noncardiovascular death
Undetermined death
32.5%
(n=40)
19.5%
(n=24)
4.1% (n=5)
14.6
(n=18)
29.3%
(n=36)
2.1% (n=2)
48.5%
(n=47)
4.1% (n=4)15.5%(n=15)
24.6%
(n=24)
5.2% (n=5)
10.5% (n=6) 5.3% (n=3) 21.5% (n=17)
2.5% (n=2)
8.8%
(n=5)
50.9%
(n=29) 8.8%
(n=5)
15.7%
(n=9)
41.8%
(n=33)
7.6%
(n=6)
17.7%
(n=14)
8.9%
(n=7)
A
B
Causes of death in the SYNTAX (A) randomized cohort and (B) nested registries. CABG ¼ coronary artery bypass grafting; CHF ¼ congestive heart failure;
MI ¼ myocardial infarction; Other Cardiac ¼ arrhythmia and all other cardiac deaths; PCI ¼ percutaneous coronary intervention; SYNTAX ¼ TAXUS
Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries.
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46to CHF and/or other cardiac causes (HR: 5.97; 95% CI:
1.72 to 20.78; p ¼ 0.005) (Figure 4C). In CABG patients,
there was no increased risk in any speciﬁc causes of
death associated with incomplete revascularization
(Figure 4C).
PATIENT CHARACTERISTICS AND PREDICTORS OF
ALL-CAUSE AND CARDIAC DEATH. Randomized
tr ia l . Signiﬁcant baseline and lesion characteristics of
patients who were alive or dead at 5 years after revas-
cularization are summarized in Table 2 (complete re-
sults are in the Online Table 1). Patients who died after
both PCI or CABG had a higher risk proﬁle at baseline
than those who were still alive; they were older,
had a higher presence of co-morbidities (diabetes,
peripheral vascular disease, chronic obstructive pul-
monary disease, carotid artery disease, and creatinine
>200 mmol/l), which resulted in higher EuroSCORE
values. Moreover, rates of medically treated diabetes
and the mean SYNTAX score were signiﬁcantly higherin patients who died after PCI, but these rates were
not higher in patients who died after CABG.
Inmultivariate analysis, PCI versus CABG treatment
was not an independent predictor of all-cause death.
Although, in the overall model, as well as in the
separate PCI and CABG models, numerous baseline
variables, such as older age and the presence of co-
morbidities, were independent predictors (Table 3).
Moreover, procedural events such as incomplete
revascularization, post-procedural prescription of
medication as secondary prevention, and the occur-
rence of nonfatal adverse events were predictive of
all-cause death. In separate models, results were
largely similar, although incomplete revasculariza-
tion, medically treated diabetes and left ventricular
function were only predictors in the PCI model and not
in the CABG model (Table 3). In contrast, renal failure
and chronic obstructive pulmonary disease were only
predictors in the CABG model.
FIGURE 2 Kaplan-Meier Cumulative Event Curves by Speciﬁc Causes of Deaths in the SYNTAX Randomized Cohort
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47Treatment with PCI versus CABG was an inde-
pendent predictor of cardiac death (HR: 1.55; 95%
CI: 1.0 to 2.33; p ¼ 0.045) (Table 4). Furthermore,
the independent predictors in the overall and PCI
models for cardiac death were nearly identical as
for all-cause death (Table 4). An additional predictor
for cardiac events after PCI was the SYNTAX score.
The CABG model included previous MI and by-
pass time as additional independent predictors,whereas other baseline characteristics no longer
were predictors.
Nested reg ist r ies . Baseline and procedural charac-
teristics of patients alive at the end of follow-up and
patients who died during follow-up are reported in
the Online Table 2. In the multivariate models that
predicted all-cause and cardiac death, results were
relatively similar to the randomized cohort, with a
number of baseline, procedural, and post-procedural
FIGURE 3 The Kaplan-Meier Cumulative Event Curves by Speciﬁc Causes of Deaths in the SYNTAX Nested Registries
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48variables as independent predictors (Table 5). Of note,
in the PCI registry, LM disease and the SYNTAX score
were predictors.
DISCUSSION
The present study provides crucial perspectives on
causes of death within the SYNTAX trial at 5-year
follow-up (Central Illustration). Our ﬁndings indicate
that treatment with CABG signiﬁcantly reduces car-
diac death compared with PCI, which was due
exclusively to a lower incidence of MI-related death.
Particularly in patient groups with 3VD and/or a
SYNTAX score $33, cardiac death was signiﬁcantly
higher after PCI than CABG. Numerous patient base-
line characteristics were independent predictors of
death, although procedural characteristics (e.g.,
incomplete revascularization), the use of speciﬁc
medications, and events during follow-up (e.g.,
nonfatal MI) also contributed in predicting all-cause
and cardiac death.
Similarly to previous randomized trials that
compared CABG with PCI using bare-metal stents,
long-term rates of all-cause mortality were compara-
ble between CABG and PCI (15,16). Despite the inclu-
sion of patients with more complex disease, such as
LM and 3VD, rates of all-cause death in the SYNTAX
trial were comparable to that of previous trials. For
the patients treated with CABG, this might be the
result of more reﬁned operative techniques and
conduit choices, among others. For patients who
underwent PCI, factors that might have contributedto lowering adverse events during follow-up were the
ﬁrst-time implantation of DES and the increased use
of dual antiplatelet therapy. In a recent report on
trends in long-term, cause-speciﬁc death after PCI,
Spoon et al. (17) found that rates of deaths were
similar from 1991 to 2012, whereas in more recent
procedures, deaths occurred less often from cardiac
causes.
Unfortunately, many previous analyses from ran-
domized trials were limited by few speciﬁcs on the
causes of cardiac deaths. Anecdotal evidence sug-
gested that the advantage of CABG over medical
therapy was particularly driven by reduced rates of
sudden cardiac death (5,6,18). A recent analysis of
deaths that occurred in the STICH (Surgical Treat-
ment for Ischemic Heart Failure) trial showed that
CABG further reduced rates of fatal MI (18). Compar-
ative analyses regarding causes of death between
CABG and PCI are restricted to a single observational
study of approximately 10,000 patients with 140
sudden cardiac deaths, in which there was no differ-
ence in the rate of sudden cardiac death after CABG
versus PCI (19).
In the present analysis, there was a signiﬁcant
difference in rates of cardiac death between CABG
and PCI. Rates of sudden cardiac death were compa-
rable, but MI-related deaths were signiﬁcantly lower
after CABG. The majority of deaths among patients
who underwent PCI were related to MI, which
accounted for nearly 50% of the total cardiac deaths.
In the BARI 2D (Bypass Angioplasty Revascularization
Investigation 2 Diabetes) trial, the reduction in the
FIGURE 4 Hazard Ratios of CABG versus PCI Subgroup Analyses
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(A) Cardiac cause of deaths within subgroups according to diabetes, left main (LM) or 3-vessel disease, and SYNTAX score. (B) Speciﬁc causes of cardiac deaths within
subgroups according to diabetes, LM, or 3-vessel disease, and SYNTAX score. (C) Causes of deaths based on revascularization status (incomplete vs. complete) in PCI and
CABG groups. CI ¼ conﬁdence interval; CR ¼ complete revascularization; HR ¼ hazard ratio; ICR ¼ incomplete revascularization; other abbreviations as in Figures 1 and 2.
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TABLE 2 Baseline Characteristics of the Patients in the SYNTAX Randomized Cohort Who Completed 5-Year Follow-Up
PCI (n ¼ 871) CABG (n ¼ 805)
Alive
(n ¼ 748)
Death
(n ¼ 123) p Value
Alive
(n ¼ 708)
Death
(n ¼ 97) p Value
Demographics
Male 581 (77.7) 82 (66.7) 0.008 563 (79.5) 81 (83.5) 0.36
Age, yrs 64.6  9.6 69.7  8.6 <0.0001 64.1  9.5 70.6  8.1 <0.0001
Medically treated diabetes 177 (23.7) 44 (35.8) 0.004 165 (23.3) 29 (29.9) 0.15
Any 112 (15.0) 24 (19.5) 0.20 96 (13.6) 16 (16.5) 0.43
Requiring insulin 65 (8.7) 20 (16.3) 0.009 69 (9.7) 13 (13.4) 0.26
Hypertension 540 (72.7) 98 (81.0) 0.054 534 (75.9) 80 (84.2) 0.07
Peripheral vascular disease 50 (6.7) 26 (21.1) <0.0001 59 (8.3) 25 (25.8) <0.0001
Unstable angina 206 (27.5) 46 (37.4) 0.025 194 (27.4) 26 (26.8) 0.90
Stabile angina 435 (58.2) 61 (49.6) 0.08 430 (60.7) 45 (46.4) 0.007
Creatinine >200 mmol/l 6 (0.8) 4 (3.3) 0.018 8 (1.1) 6 (6.2) <0.0001
Pulmonary hypertension 7 (0.9) 1 (0.8) 0.90 6 (0.8) 3 (3.1) 0.049
Previous MI 217 (29.4) 54 (44.3) 0.001 227 (32.4) 36 (37.9) 0.28
Carotid artery disease 52 (7.0) 17 (13.8) 0.009 50 (7.1) 17 (17.5) <0.0001
Chronic obstructive pulmonary disease 52 (7.0) 16 (13.0) 0.02 57 (8.1) 18 (18.6) 0.001
LVEF
Moderate (30%–49%) 119 (16.3) 34 (28.3) 0.002 119 (17.0) 20 (20.6) 0.37
Poor (<30%) 5 (0.7) 7 (5.8) <0.0001 12 (1.7) 5 (5.2) 0.028
Baseline anatomical and clinical scores
SYNTAX score 27.9  11.4 32.4  11.3 <0.0001 29.0  11.3 30.6  12.3 0.19
Additive EuroScore 3.2  2.3 5.3  3.0 <0.0001 3.1  2.3 4.9  2.9 <0.0001
Total Parsonnet score 7.9  6.6 12.3  7.7 <0.0001 7.6  6.3 13.1  7.9 <0.0001
Left main disease 301 (40.2) 45 (36.6) 0.44 273 (38.6) 49 (50.5) 0.024
Procedural characteristics
Bypass time (min) — — — 84.8  32.6 93.1  48.1 0.046
No. of grafts — — — 2.8  0.7 2.6  0.8 0.036
No. of distal anastomoses — — — 3.2  0.9 3.0  1.0 0.026
No. of stents implanted 4.6  2.3 5.0  2.2 0.053 — — —
Staged procedure 97 (13.0) 27 (22.0) 0.008 — — —
Incomplete revascularization 317 (42.7) 71 (58.2) 0.001 260 (36.4) 38 (40.9) 0.40
Treatments at baseline
ARB or ACE inhibitor 432 (57.8) 83 (67.5) 0.042 441 (62.3) 73 (75.3) 0.013
Beta-blocker 555 (74.2) 89 (72.4) 0.67 563 (79.5) 64 (66.0) 0.003
Amiodarone 8 (1.1) 4 (3.3) 0.054 5 (0.7) 1 (1.0) 0.73
Cardiac glycoside 5 (0.7) 3 (2.4) 0.056 4 (0.6) 3 (3.1) 0.012
Diuretics 163 (21.8) 46 (37.4) <0.0001 149 (21.0) 31 (32.0) 0.016
Treatments at discharge
Acetylsalicylic acid 641 (86.4) 56 (45.9) <0.0001 593 (83.9) 32 (34.0) <0.0001
Thienopyridine antiplatelet 238 (32.1) 34 (27.9) 0.35 94 (13.3) 2 (2.1) 0.002
ARB or ACE inhibitor 547 (73.1) 44 (35.8) <0.0001 514 (72.6) 35 (36.1) <0.0001
Beta-blocker 572 (76.4) 52 (42.6) <0.0001 529 (74.9) 36 (37.1) <0.0001
Amiodarone 13 (1.7) 7 (5.7) 0.006 15 (2.1) 4 (4.1) 0.22
Statin 631 (85.0) 51 (41.8) <0.0001 610 (86.3) 28 (29.8) <0.0001
Values are n (%) or mean  SD.
ARB ¼ angiotensin receptor blocker; ACE ¼ angiotensin-converting enzyme; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; other abbreviations as in
Table 1.
Milojevic et al. J A C C V O L . 6 7 , N O . 1 , 2 0 1 6
Cause of Death in the SYNTAX Trial J A N U A R Y 5 / 1 2 , 2 0 1 6 : 4 2 – 5 5
50composite of death, stroke, and MI with CABG versus
medical therapy was driven largely by a reduction
in MI, whereas the PCI versus medical therapy
analysis showed similar rates of MI among the
2 groups (20). These ﬁndings emphasize the impor-
tance of MI reduction after PCI. Overall, use of
the newer-generation DES (21) and default use offractional ﬂow reserve (22) are considered to reduce
the rate of MI and death by reducing events of
stent thrombosis and restenosis in more contempo-
rary trials. The impact of prolonged use and the exact
duration of dual antiplatelet therapy on ischemic
events remain topics of debate (23,24). Neverthe-
less, de novo lesions in patients who previously
TABLE 4 Independent Predictors of Cardiac Mortality in the
SYNTAX Randomized Cohort
HR (95% CI) p Value
SYNTAX randomized cohort
PCI treatment vs. CABG 1.55 (1.09–2.33) 0.045
Age (per 5-yr increase) 1.16 (1.04–1.31) 0.009
Peripheral vascular disease 2.55 (1.64–3.98) <0.0001
LVEF poor (<30%) 5.08 (1.97–13.12) 0.001
LVEF moderate (30%–49%) 1.76 (1.15–2.69) 0.009
Previous MI 1.69 (1.14–2.50) 0.010
Incomplete revascularization 1.67 (1.13–2.45) 0.010
ARB or ACE inhibitor use at discharge 0.58 (0.37–0.92) 0.020
Acetylsalicylic acid use at discharge 0.54 (0.34–0.86) 0.010
Statins use at discharge 0.25 (0.16–0.41) <0.0001
Nonfatal MI during follow-up 6.16 (3.98–9.53) <0.0001
PCI group
Peripheral vascular disease 2.79 (1.54–5.71) 0.001
LVEF poor (<30%) 1.83 (1.26–3.15) 0.006
LVEF moderate (30%–49%) 3.06 (1.84–5.57) <0.0001
SYNTAX score 1.03 (1.01–1.05) 0.016
Incomplete revascularization 1.83 (1.15–3.24) 0.011
ARB or ACE inhibitor use at discharge 0.48 (0.27–0.81) 0.007
Acetylsalicylic acid use at discharge 0.46 (0.26–0.88) 0.018
Statins use at discharge 0.39 (0.21–0.58) <0.0001
Nonfatal MI during follow-up 6.79 (4.24–10.72) <0.0001
CABG group
Peripheral vascular disease 4.10 (1.88–8.97) <0.0001
Creatinine blood level >200 mmol/l 5.65 (1.19–26.81) 0.029
Prior MI 2.35 (1.14–4.81) 0.020
Bypass time (min) 1.01 (1.00–1.02) 0.009
Acetylsalicylic acid use at discharge 0.37 (0.16–0.83) 0.016
Statins use at discharge 0.29 (0.18–0.44) <0.0001
Nonfatal MI during follow-up 7.25 (2.39–22.02) <0.0001
C-statistics for the models were: overall, 0.72 (95% CI: 0.67 to 0.77; p < 0.0001);
PCI, 0.70 (95% CI: 0.64 to 0.76; p < 0.0001); CABG, 0.75 (95% CI: 0.66 to 0.83;
p < 0.0001).
Abbreviations as in Tables 1 to 3.
TABLE 3 Independent Predictors of All-Cause Mortality in the
SYNTAX Randomized Cohort
HR (95% CI) p Value
SYNTAX randomized cohort
Age (per 5-yr increase) 1.25 (1.15–1.36) <0.0001
Medically treated diabetes 1.36 (1.01–1.84) 0.042
Peripheral vascular disease 2.04 (1.46–2.83) <0.0001
LVEF poor (<30%) 4.47 (2.31–8.66) <0.0001
Previous MI 1.31 (1.01–1.75) 0.044
Incomplete revascularization 1.37 (1.03–1.81) 0.029
Beta-blocker use at discharge 0.66 (0.47–0.93) 0.019
ARB or ACE inhibitor use at discharge 0.49 (0.35–0.69) <0.0001
Acetylsalicylic acid use at discharge 0.47 (0.33–0.67) <0.0001
Statin use at discharge 0.27 (0.19–0.39) <0.0001
Nonfatal CVA during follow-up 2.07 (1.12–2.95) 0.032
Nonfatal MI during follow–up 3.86 (2.69–5.53) <0.0001
PCI group
Age (per 5-yr increase) 1.25 (1.11–1.40) 0.008
Medically treated diabetes 1.66 (1.09–2.53) 0.018
Peripheral vascular disease 2.77 (1.73–4.44) <0.0001
LVEF poor (<30%) 2.26 (1.67–3.07) <0.0001
LVEF moderate (30%–49%) 2.37 (1.54–3.63) <0.0001
Incomplete revascularization 1.73 (1.17–2.58) 0.007
Beta-blocker use at discharge 0.59 (0.37–0.97) 0.036
ARB or ACE inhibitor use at discharge 0.43 (0.27–0.68) <0.0001
Acetylsalicylic acid use at discharge 0.52 (0.32–0.85) 0.008
Statin use at discharge 0.43 (0.27–0.69) 0.001
Nonfatal MI during follow-up 5.49 (3.68–9.14) <0.0001
CABG group
Age (per 5-yr increase) 1.27 (1.09–1.48) 0.002
Peripheral vascular disease 2.01 (1.14–3.54) 0.016
Creatinine blood level >200 mmol/l 4.75 (1.38–16.41) 0.014
Chronic obstructive pulmonary disease 1.92 (1.05–3.48) 0.033
ARB or ACE inhibitor use at discharge 0.52 (0.28–0.94) 0.033
Acetylsalicylic acid use at discharge 0.39 (0.20–0.74) 0.004
Statin use at discharge 0.28 (0.20–0.43) <0.0001
Nonfatal MI during follow-up 3.88 (1.60–9.39) 0.003
C-statistics for the models were: overall, 0.71 (95% CI: 0.68 to 0.75; p < 0.0001);
PCI, 0.74 (95% CI: 0.69 to 0.79; p < 0.0001); CABG, 0.71 (95% CI: 0.65 to 0.76;
p < 0.0001).
Abbreviations as in Tables 1 to 3.
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51underwent PCI can progress to cause MI and subse-
quently death, whereas after CABG, the signiﬁcance
of such lesions with an existing patent bypass graft is
limited. Even with the use of second-generation DES,
the rate of spontaneous MI continues to be higher
after PCI than CABG (25). Moreover, the lower rates of
MI-related deaths with CABG might result from more
complete revascularization and subsequently lower
areas of ischemic myocardium (6,26). These concepts
were validated in several studies that demonstrated
that CABG had more durable protection against MI in
patients with extensive CAD (16,27,28).
Because incomplete revascularization with PCI
occurs more often in patients with highly complexlesions, and speciﬁcally chronic total occlusions
(26,29), the present results emphasize these differ-
ences between CABG and PCI in the cardiac death
subgroup analyses according to SYNTAX score ter-
tiles. In the highest SYNTAX score tertiles, patients
who underwent PCI had a higher risk of MI-related
death and sudden cardiac deaths. Patients with
complex disease undergoing PCI have a continued
higher risk of stent thrombosis, which is related to
cardiac death (30). In patients with complex disease
and incomplete revascularization, lesions without
revascularization have a considerable risk of pro-
gressing to acute events, a similar ﬁnding as in an
analysis of the BARI trial that showed that revas-
cularization versus no revascularization reduced
the rate of sudden cardiac death (6). Moreover, pro-
gression of disease in patients with complex disease
and higher SYNTAX scores may be enhanced because
TABLE 5 Independent Predictors of All-Cause and Cardiac Mortality in the
SYNTAX Nested Registries
HR (95% CI) p Value
PCI registry
All-cause mortality
Age (per 5-yr increase) 1.44 (1.23–1.68) <0.0001
Chronic obstructive pulmonary disease 1.90 (1.01–3.59) 0.047
LVEF poor (<30%) 3.19 (1.33–7.65) 0.009
Left main disease 2.29 (1.25–4.19) 0.007
Previous MI 1.88 (1.04–3.41) 0.037
Beta-blocker use at discharge 0.52 (0.28–0.96) 0.038
Nonfatal MI during follow-up 2.50 (1.07–5.83) 0.033
Cardiac mortality
Age (per 5-yr increase) 1.53 (1.11–2.09) 0.008
Medically treated diabetes 5.56 (1.40–22.03) 0.015
Creatinine blood level >200 mmol/l 12.18 (1.51–80.44) 0.019
Left main disease 5.66 (1.52–21.10) 0.010
Previous MI 6.65 (1.91–23.15) 0.003
SYNTAX score 1.09 (1.04–1.14) <0.0001
CABG registry
All-cause mortality
Age (per 5-yr increase) 1.21 (1.04–1.41) 0.015
Medically treated diabetes 2.22 (1.34–3.70) 0.002
Chronic obstructive pulmonary disease 3.32 (1.79–6.17) <0.0001
LVEF moderate (30%–49%) 2.24 (1.33–3.78) 0.002
Procedure time (min) 1.01 (1.00–1.02) <0.0001
Acetylsalicylic acid use at discharge 0.41 (0.22–0.76) 0.004
Nonfatal MI during follow-up 2.54 (1.08–5.96) 0.033
Cardiac mortality
LVEF moderate (30%–49%) 4.05 (1.66–9.87) 0.002
Acetylsalicylic acid use at discharge 0.30 (0.18–0.80) 0.009
Nonfatal MI during follow-up 5.29 (1.52–18.41) 0.016
Abbreviations as in Tables 1 to 3.
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52of a higher risk proﬁle (e.g., diabetes, hypertension,
and so on) that furthermore increases the risk of
adverse events (31). These considerations contributed
to the selection of less complex LM disease in the
EXCEL (Evaluation of the Xience Everolimus-Eluting
Stent Versus Coronary Artery Bypass Surgery for
Effectiveness of Left Main Revascularization) ran-
domized comparison between CABG and LM stenting
with current generation DES.
In subgroups according to diabetes, the difference
between PCI and CABG in cardiac death was greater
in diabetic patients than in nondiabetic patients,
whereas the difference in all-cause death was not
signiﬁcant in diabetic patients (32). This is notable in
the BARI publication (33), but not in the results of the
recent FREEDOM (Future Revascularization Evalua-
tion in Patients with Diabetes Mellitus: Optimal
Management of Multivessel Disease) trial, which re-
sults were in favor of CABG in terms of all-cause
death and comparable outcomes in cardiovascular
death (34). This may reﬂect the relatively low numberof events of cardiac or cardiovascular death and the
play of chance that may play a role. In other subgroup
analyses, the signiﬁcant increases in cardiac deaths
that were observed after PCI in patients with 3VD
strengthens the ﬁnding that these patients particu-
larly beneﬁted from CABG (35). Conversely, consis-
tent with other studies of patients with LM diseases,
cardiac death was not different between PCI and
CABG (25,36), justifying the hypothesis on which the
current EXCEL trial is based (NCT01205776).
Multivariate models identiﬁed several distinct
variables associated with long-term all-cause and
cardiac death that may aid decisions regarding
revascularization strategies. In comparison with pre-
viously published studies that identiﬁed predictors
of long-term mortality (33,37,38), our results add
signiﬁcantly to the current body of evidence. Long-
term analyses of all-cause mortality may lose accu-
racy in determining the relevance of myocardial
revascularization to the occurrence of death, whereas
analysis of cardiac death as adjudicated by a CEC may
provide a more clear distinction between death as a
result of comorbidities or as the consequence of CAD.
Furthermore, the majority of models to predict death
included only preoperative values. The present ana-
lyses also emphasized the importance of nonfatal
adverse events (stroke and MI) as predictors of future
fatal events. We identiﬁed that a nonfatal stroke was
a signiﬁcant predictor of death, which corresponds
with the association between stroke and subsequent
increased risk not only of repeated stroke, but also of
the combined risk of stroke and MI (39). In addition, a
nonfatal MI was associated with an increased risk of
all-cause and cardiac mortality. This might be the
result of progressive heart failure because our ﬁnd-
ings also showed that patients with a moderate or
poor left ventricular ejection fraction and a history of
MI are at an increased risk of MI-related death.
Therefore, prevention of MI after treatment with PCI,
but also after CABG, is of critical importance for sur-
vival. As shown in our multivariate analyses, as well
as in several other studies, the importance of sec-
ondary prevention medication is essential in this re-
gard. Iqbal et al. (40) recently showed that the impact
of secondary prevention medication was even larger
than the impact of performing PCI or CABG in
patients with complex CAD. Guideline-directed
medical therapy should be a principal strategy for
all patients with CAD, as also recently shown
in an analysis of BARI 2D data (41). This informa-
tion on predictors may be particularly useful for
the Heart Team currently when both PCI and
CABG are excellent treatment options; the Heart
Team should not only determine the most optimal
CENTRAL ILLUSTRATION Causes of Deaths in the SYNTAX Randomized Cohort: PCI and CABG Comparison
Milojevic, M. et al. J Am Coll Cardiol. 2016; 67(1):42–55.
After percutaneous coronary intervention (PCI), the leading cause of cardiovascular death was myocardial infarction (MI)-related death. After coronary artery bypass
grafting (CABG), the leading cause of cardiovascular death was congestive heart failure (CHF), arrhythmia, or other causes (e.g., arrhythmia and all other
cardiac deaths).
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53revascularization strategy, but which strategy might
also be useful when integrated into the post-
procedural phase (7).
STUDY LIMITATIONS. The present study represents a
post-hoc analysis; therefore, the results should be
regarded as exploratory and hypothesis-generating.
Moreover, a great number of subgroup analyses
have been reported, so results should be interpreted
with caution because some differences may be the
results of chance (42). Although the SYNTAX trial was
an all-comers randomized trial, inclusion of patients
in a randomized trial is limited to speciﬁc inclusion
and exclusion criteria; therefore, the external val-
idity, which reﬂects actual patients in the real-world,
may be suboptimal.
Despite the primarily used SYNTAX trial classiﬁ-
cations, the determination of cause-speciﬁc deathcould not always be established. This is particularly
relevant to the subcategories of cardiac death in
which absolute precision may not always be possible.
However, bias was limited by event adjudication by
a blinded committee of physician experts using
previous standardized deﬁnitions.
Autopsy was performed in a low number of cases
(n ¼ 38, 10.7%); therefore, the rate of death related
to MI could be underestimated, considering that MI
might be involved in the process of heart failure and
cardiac rupture, as well as sudden cardiac death.
We did not have information on post-procedural
occurrence of additional co-morbidities, which could
affect the established groups of predictors.
Although medication use was recorded throughout
different time points during follow-up, there were
no data on compliance rates or on reasons for
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: For
patients with complex coronary disease, CABG was
associated with a lower rate of cardiac death after
5 years than PCI, and patients who underwent PCI
with ﬁrst-generation DES were at higher risk of
fatal MI than those managed with CABG.
TRANSLATIONAL OUTLOOK: Additional random-
ized studies in patients undergoing PCI with newer
generation DES should examine predictors of
MI-related death.
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54discontinuation of medication. Moreover, at later
follow-up with longer periods between collection
of medication data (e.g., 2 years), we were unable
to determine the exact date of medication discontin-
uation. Therefore, we could not assess the impact of
medication use during follow-up on death rates.
CONCLUSIONS
For patients with complex CAD, CABG compared with
PCI did not reduce all-cause death, but was shown
to be associated with a signiﬁcantly reduced rate
of cardiac death that was driven primarily by a
reduction of death as a consequence of MI. This
reduction was greatest in patients with diabetes, 3VD,
or a SYNTAX score $33. Although PCI is becoming
a more acceptable revascularization strategy for
patients with LM or 3VD, treatments following PCI
should target reducing post-revascularization spon-
taneous MI, because this remains the leading cause
of death after PCI.REPRINT REQUESTS AND CORRESPONDENCE: Prof.
David R. Holmes, Jr., Division of Cardiovascular Dis-
eases and Internal Medicine, Mayo Clinic Rochester,
Rochester, Minnesota 55905. E-mail: holmes.david@
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